U.S. Oral GLP-1 Therapeutics Market to Reach USD 70.50 Billion and Europe USD 19.72 Billion by 2035 as Oral Wegovy Approval, Non-Peptide Candidates, and Telehealth Access Drive Growth.

Austin, United States, Sept. 10, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Oral GLP-1 Therapeutics Market was valued at USD 6.81 Billion in 2025 and is projected to reach USD 137.36 Billion by 2035, registering a CAGR of 35.0% from 2026 to 2035. The market is revolutionizing the way diabetes and obesity are treated, offering the same effectiveness of injectable GLP-1 receptor agonists through the pain-free daily process of taking an oral medication. The growth of the market is driven by the FDA approval of oral semaglutide Wegovy for chronic weight management, intense competition among pharmaceutical companies to release non-peptide products, and fast development of production capacity.


Download the Oral GLP-1 Therapeutics Market Sample Report: https://www.snsinsider.com/sample-request/10858

Oral GLP-1 Therapeutics Market Key Highlights

  • Market size, 2025: USD 6.81 Billion
  • Market forecast, 2035: USD 137.36 Billion
  • CAGR: 35.0% from 2026 to 2035
  • Largest region: North America, approximately 62.0% share in 2025
  • Fastest-growing region: Asia Pacific, approximately 42.0% CAGR
  • Largest product: Semaglutide (Rybelsus/Oral Wegovy), approximately 78% share in 2025
  • Fastest-growing product: Orforglipron
  • Largest indication: Type 2 Diabetes Management, approximately 54% share in 2025
  • Fastest-growing indication: Obesity & Weight Management
  • Largest formulation technology: SNAC-Based Peptide Formulation, approximately 71% share in 2025
  • Fastest-growing formulation technology: Non-Peptide Small Molecule Formulation
  • Largest distribution channel: Retail Pharmacies, approximately 58% share in 2025
  • Fastest-growing distribution channel: Online Pharmacies

Market Relevance

Oral GLP-1 agents represent a groundbreaking development in the management of metabolic disorders by providing a non-injectable mode of treatment that was available only via injectable therapies. The strong preference of patients and doctors for a convenient oral therapy over injection-based treatment has transformed the way diabetes and obesity are managed; the FDA’s historic approval of oral Wegovy has paved the way for a much bigger pool of patients than what existed earlier in the diabetes-only segment.

Oral GLP-1 Therapeutics Market Overview

The market consists of SNAC-based formulations of peptide and non-peptide small molecules for type 2 diabetes and obesity indications sold via retail and online pharmacies. Semaglutide, which is being developed using the proprietary absorption enhancer technology from Novo Nordisk in Rybelsus and oral Wegovy, currently stands as the only commercially approved way to deliver GLP-1 through the oral route, whereas non-peptide alternatives like orforglipron are making headway in late-stage studies.

Strategic Market Outlook

Potential opportunities for market expansion include the increasing investments in small molecule oral GLP-1 therapies that are free from the need to be taken according to meal times and are smaller in size than peptides. The second potential area for expansion is in the provision of treatments where there are treatment gaps in developing pharmaceutical markets since there is demand created through government policies to deal with the growing prevalence of diabetes and obesity.

Higher costs of treatments and production capacities are the key restraints to the development of such therapies. Costs involved in therapy make it unaffordable to many patients and the number of patients who require such treatments is much higher than the increased production capacities of pharmaceutical companies.

Oral GLP-1 Therapeutics Market Regional Analysis

North America was leading the industry with a share of 62.0% in 2025, owing to the market’s status as the first commercial market for Rybelsus and oral Wegovy, good FDA regulations, and high consumer and employer demand for non-needle therapy. The U.S. comprised around 90.00% of the North American market value, supported by strong commercial launches of oral Wegovy.

The U.S. Oral GLP-1 Therapeutics Market was valued at approximately USD 3.80 Billion in 2025 and is projected to reach approximately USD 70.50 Billion by 2035, registering a CAGR of approximately 34.0% from 2026 to 2035.

Europe Oral GLP-1 Therapeutics Market had around 21.00% share of the global market, with the market size reaching USD 1.43 Billion in 2025, and it is expected to touch USD 19.72 Billion by 2035 at a CAGR of 30.00% during 2026-2035. The growth in the region is driven by increasing prevalence of type 2 diabetes and obesity and increasing discussions on reimbursement nationally. Germany held around 21.50% of Europe revenue in 2025, helped by strong pharmaceutical market infrastructure and high per capita diabetes and obesity treatment rate.

Asia Pacific is showing the fastest growth rate across all regions, at a CAGR of about 42.0% from 2026-2035, owing to rapid rise in prevalence of diabetes and obesity and rising capacity of domestic pharmaceutical manufacturing. China held around 26.80% of regional revenue in 2025, owing to its fast-growing domestic GLP-1 pipeline with companies such as Innovent Biologics, Gan & Lee Pharmaceuticals, and Sciwind Biosciences.

Middle East & Africa: Saudi Arabia accounted for approximately 24.50% of regional revenue in 2025, supported by significant healthcare industry investment.

Latin America: Brazil led regional revenue at approximately 32.90% in 2025, supported by growing diabetes treatment adoption and pharmaceutical distribution.

Buy the Oral GLP-1 Therapeutics Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10858

Oral GLP-1 Therapeutics Market Segment Analysis

By Product: Semaglutide (Rybelsus/Oral Wegovy) captured about 78% market share in 2025 due to the first mover advantage enjoyed by Novo Nordisk and the FDA approval of Oral Wegovy in December 2025 for long-term weight management. Orforglipron is the fastest growing segment because of Eli Lilly’s promising results from the phase 3 ATTAIN-1 study and significant investment of USD 6.5 billion.

By Indication: Type 2 Diabetes Management held 54% market share in 2025 as a result of the initial approval of Rybelsus prior to the approval of the oral GLP-1s' indication for obesity. The indication with the highest growth potential is Obesity & Weight Management, owing to the FDA approval of oral Wegovy in December 2025.

By Formulation Technology: Market Share of SNAC-Based Peptide Formulation was estimated at 71% in 2025, with Novo Nordisk's unique absorption enhancer technology being the only commercial form of oral GLP-1 delivery technology approved till date. Non-Peptide Small Molecule Formulation is one of the rapidly growing technologies due to orforglipron, aleniglipron, and CT-996 not requiring timed diet.

By Distribution Channel: Retail pharmacies captured about 58% market share in 2025 owing to their strong prescription-dispensing structure and geographical reach. Online Pharmacies have been experiencing the highest growth rates owing to telehealth and digital health companies connecting prescribers and patients via online services.

Oral GLP-1 Therapeutics Market Key Trends

  • Explosive growth continuing following FDA approval of oral semaglutide Wegovy for chronic weight management
  • Intense pharmaceutical competition as companies race to bring next-generation non-peptide oral candidates to market
  • Rapid manufacturing capacity expansion as leading companies invest billions in dedicated oral GLP-1 production
  • Growing telehealth and online pharmacy prescribing expanding patient access to oral GLP-1 therapies
  • Rising indication expansion beyond diabetes and obesity broadening the addressable patient population

Competitive Landscape

The Oral GLP-1 Therapeutics Market includes established metabolic disease pharmaceutical leaders and specialty biotechs, with competition centred on non-peptide small-molecule candidate development and manufacturing scale-up.

In 2025, Novo Nordisk A/S received FDA approval for its oral semaglutide Wegovy pill (25 mg), the first oral GLP-1 therapy approved for chronic weight management. In 2026, Eli Lilly and Company reported positive Phase 3 ATTAIN-1 trial results for orforglipron, supporting planned global regulatory submissions, having announced a USD 6.5 billion investment in 2025 to build a new manufacturing facility in Houston, Texas dedicated to the candidate. In 2026, Structure Therapeutics Inc. reported positive Phase II results for its oral GLP-1 agonist aleniglipron. In 2025, Pfizer Inc. discontinued development of danuglipron, its oral GLP-1 receptor agonist being investigated for chronic weight management.

Major key players include

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Roche Holding AG
  • Structure Therapeutics Inc.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Sanofi S.A.
  • Sciwind Biosciences Co., Ltd.
  • Gan & Lee Pharmaceuticals
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • QL Biopharmaceutical Co., Ltd.
  • PegBio Co., Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Kallyope, Inc.
  • Rani Therapeutics Holdings, Inc.
  • Oramed Pharmaceuticals Inc.

Explore the Complete Oral GLP-1 Therapeutics Market Report: https://www.snsinsider.com/reports/oral-glp-1-therapeutics-market-10858

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com